2.50
Hdl Handle:
http://hdl.handle.net/10033/621281
Title:
Optimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy.
Authors:
Felgner, Sebastian; Kocijancic, Dino; Frahm, Michael; Curtiss, Roy; Erhardt, Marc; Weiss, Siegfried
Abstract:
Bacteria-mediated tumor therapy using Salmonella enterica serovar Typhimurium is a therapeutic option with great potential. Numerous studies explored the potential of Salmonella Typhimurium for therapeutic applications, however reconciling safety with vectorial efficacy remains a major issue. Recently we have described a conditionally attenuated Salmonella vector that is based on genetic lipopolysaccharide modification. This vector combines strong attenuation with appropriate anti-tumor properties by targeting various cancerous tissues in vivo. Therefore, it was promoted as an anti-tumor agent. In this addendum, we summarize these findings and demonstrate additional optimization steps that may further improve the therapeutic efficacy of our vector strain.
Affiliation:
Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
Citation:
Optimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy. 2016, 7 (2):171-7 Gut Microbes
Journal:
Gut microbes
Issue Date:
2016
URI:
http://hdl.handle.net/10033/621281
DOI:
10.1080/19490976.2016.1155021
PubMed ID:
26939530
PubMed Central ID:
PMC4856459
Additional Links:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856459/
Type:
Article
Language:
en
ISSN:
1949-0984
Appears in Collections:
publications of the research group molecular Immunology (MOLI); publications of the junior research group infection biology of Salmonella (IBIS)

Full metadata record

DC FieldValue Language
dc.contributor.authorFelgner, Sebastianen
dc.contributor.authorKocijancic, Dinoen
dc.contributor.authorFrahm, Michaelen
dc.contributor.authorCurtiss, Royen
dc.contributor.authorErhardt, Marcen
dc.contributor.authorWeiss, Siegfrieden
dc.date.accessioned2018-02-15T14:42:49Z-
dc.date.available2018-02-15T14:42:49Z-
dc.date.issued2016-
dc.identifier.citationOptimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy. 2016, 7 (2):171-7 Gut Microbesen
dc.identifier.issn1949-0984-
dc.identifier.pmid26939530-
dc.identifier.doi10.1080/19490976.2016.1155021-
dc.identifier.urihttp://hdl.handle.net/10033/621281-
dc.description.abstractBacteria-mediated tumor therapy using Salmonella enterica serovar Typhimurium is a therapeutic option with great potential. Numerous studies explored the potential of Salmonella Typhimurium for therapeutic applications, however reconciling safety with vectorial efficacy remains a major issue. Recently we have described a conditionally attenuated Salmonella vector that is based on genetic lipopolysaccharide modification. This vector combines strong attenuation with appropriate anti-tumor properties by targeting various cancerous tissues in vivo. Therefore, it was promoted as an anti-tumor agent. In this addendum, we summarize these findings and demonstrate additional optimization steps that may further improve the therapeutic efficacy of our vector strain.en
dc.language.isoenen
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856459/en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAnimalsen
dc.subject.meshBiological Therapyen
dc.subject.meshHumansen
dc.subject.meshImmunotherapyen
dc.subject.meshNeoplasmsen
dc.subject.meshSalmonella typhimuriumen
dc.titleOptimizing Salmonella enterica serovar Typhimurium for bacteria-mediated tumor therapy.en
dc.typeArticleen
dc.contributor.departmentHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalGut microbesen
dc.identifier.pmcidPMC4856459-

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.